Institute Of Hematology & Blood Diseases Hospital, China

This study tested a drug called dasatinib combined with standard chemotherapy in 30 adults newly diagnosed with a specific type of leukemia (Ph+ ALL). The goal was to see if the combination helps people live longer and keeps the cancer away. Patients could also receive a stem cel…

This study tested a new treatment using specially engineered immune cells (CD19 CAR T cells) in 20 adults with relapsed or hard-to-treat B-cell lymphoma. The cells were given in three doses over three days. The main goal was to check safety and see how well the treatment worked. …

This study tested a combination of three drugs (zanubrutinib, ixazomib, and dexamethasone) in 25 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The treatment was given for up to 24 months and then stopped, aiming to achieve deep remission and redu…

This study tested a new 9-day treatment plan for people with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. The treatment combined three drugs: rabbit antithymocyte globulin, cyclosporine, and levamisole. The goal was to see if thi…

This study tested a three-drug oral regimen (thalidomide, cyclophosphamide, and dexamethasone) followed by maintenance therapy (thalidomide and prednisone) in 44 adults newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see how well the treat…

This study tested a new treatment called ET-01 in 3 people with severe beta-thalassemia who need regular blood transfusions. The treatment uses the patient's own stem cells, modified to produce healthy red blood cells. The goal was to see if it is safe and can reduce or eliminate…

This study tested a two-part chemotherapy regimen (EDOCH alternating with DHAP) with or without the targeted drug rituximab in 55 younger adults (age 65 or under) newly diagnosed with mantle cell lymphoma, a rare blood cancer. The goal was to see if this approach improves how lon…

This study tested a combination of two drugs, bortezomib and dexamethasone, in 18 adults with acquired pure red cell aplasia (a rare condition where the body stops making red blood cells) whose first treatment didn't work or stopped working. The goal was to see if the combo could…

This early-phase study tested a new treatment called C-CAR088 in 9 people with multiple myeloma that had returned or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main goal was to check s…

This study tested two treatments for acquired hemophilia A, a rare condition where the immune system attacks clotting factors, causing severe bleeding. 66 adults received either steroids with cyclophosphamide or steroids with a single dose of rituximab. The goal was to see which …

This early-phase study tested a new therapy made from lab-grown natural killer (NK) cells in 2 adults with acute myeloid leukemia (AML) that had come back or was hard to treat. The goal was to see if the treatment is safe and to get a first look at whether it can reduce signs of …

This early-phase study tested a new cell therapy called LILRB4 STAR-T cells in one person with monocytic leukemia (a type of blood cancer). The goal was to see if the treatment is safe and can reduce cancer in the bone marrow. Researchers monitored side effects like immune reacti…

This study tested whether a stem cell transplant (using the patient's own cells) could help people with a high-risk form of Waldenström macroglobulinemia, a rare blood cancer, live longer compared to standard chemotherapy. The trial involved 70 adults in China who had not receive…

This early-stage study tested a new type of CAR-T cell therapy (C-CAR066) in 7 adults with diffuse large B-cell lymphoma whose cancer returned or didn't respond after a prior CAR-T treatment. The therapy targets a protein called CD20 on cancer cells. The main goals were to check …

This study tested two different drug combinations in 35 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. One group received cyclophosphamide plus dexamethasone with rituximab, and the other with bortezomib. The goal was to see which combination bett…

This study tested two low-dose rituximab schedules in 100 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The goal was to see if these regimens could safely raise platelet counts and reduce bleeding. Participant…

This early-phase study tested a new treatment called BZ019 for adults with B-cell lymphoma that came back or didn't respond to standard therapy. The treatment uses a patient's own immune cells, modified to attack cancer cells. The main goals were to check safety and see if the tr…

This study tested a drug called eltrombopag in 48 adults with chronic hepatitis B who also had a low platelet count (immune thrombocytopenia). The goal was to see if taking the drug for 6 weeks could safely raise platelet levels to reduce bleeding risk. The main measure was the n…

This study tested whether the drug lusutrombopag could safely raise platelet counts in Chinese adults with chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The trial involved 17 participants who hadn't responded well to standard first …

This study tested whether posaconazole tablets can prevent lung fungal infections in 360 patients who had a stem cell transplant. Researchers measured drug levels in the blood and checked for infections. The goal was to find the right dose to keep patients safe from these serious…

This study looked back at medical records of 60 adults with blood cancers who had a stem cell transplant and later developed a rare fungal infection called mucormycosis. Researchers compared cases before and during the COVID-19 pandemic to see how the virus, new diagnostic tools,…

This study looked back at 320 children with acute myeloid leukemia (AML) to compare two different chemotherapy treatment plans. The goal was to see if a newer plan (CAMS-2009) helped children live longer or stay cancer-free better than the older plan (CAMS-2005). The researchers …